Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & […]
Clinical Advances in Hematology & Oncology talks with Sonali M. Smith, MD, an Elwood V. Jensen Professor in Medicine and Chief, Section of Hematology/Oncology at the University of Chicago, about all things transformed lymphoma, including risk factors, distinguishing characteristics, pathogenesis, traditional treatment approaches, treatment goals, new treatment strategies, and other promising areas of research.
In this series from Blood that tackles four cases studies, the outcomes of AML pediatric patients compared to children with ALL is explored, focusing on the emerging new treatments venetoclax (Venclexta; AbbVie/Genentech), CD33- and CD123-directed CAR T-cell therapy, CD123-directed antibody therapy, and menin inhibitors.
Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates […]
In this Original Report from the Journal of Clinical Oncology, the authors conducted a phase I trial of autologous CD19 CAR T cells in children and young adults (CAYAs) with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) to discover whether the role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy can improve […]
Day two of ASCO 2020 featured late-breaking data from a phase 3 trial evaluating early local therapy in metastatic breast cancer, as well as results of the phase 3 ENDURANCE trial, the ALPHA CAR T-cell trial, and the C-144-01 trial assessing TIL therapy.